Healthcare
Tvardi Therapeutics, Inc.(TVRD)
Live Price
Offline$2.64
-2.58% today
1Y Change
-89.76%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $30.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +94.7%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tvardi Therapeutics, Inc. (TVRD) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $2.64 and down 89.8% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +94.7%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +94.7%, free cash flow +62.1% with operating margin -964.6% and ROIC -117.2%. Valuation already assumes a fairly strong business story at price/sales 11.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TVRD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
-964.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +94.7%, with operating margin around -964.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -0.8% | -6.8% | -32.2% |
2026 Mar 31, 2026 | -41.8% | -5.7% | -4.1% | -3.8% |
2025 Nov 13, 2025 | +28.9% | -1.9% | -7.1% | +7.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TVRD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TVRD Max Drawdown
-93.86%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TVRD and SPY.
Company Overview
Tvardi Therapeutics, Inc.
NASDAQ Global Market
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
- Leadership
- Imran Alibhai
- IPO Date
- Apr 16, 2025
- Employees
- 17
- Street Address
- 2450 Holcombe Blvd, Suite Xโ
- Mailing
- Sugar Land, TX, 77021
- Region
- Sugar Land, TX, US
- Reporting Currency
- USD
- Investor Line
- 832-413-1362
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 11.5
- Price/Book
- 1.4
Growth
- Revenue
- -100.0%
- EPS
- +94.7%
- Free Cash Flow
- +62.1%
Profitability
- Gross Margin
- 98.2%
- Operating Margin
- -964.6%
- Net Margin
- -527.1%
- ROE
- -81.3%
- ROIC
- -117.2%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 2.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.